Correction: Juhás et al. Improving Antimicrobial Activity and Physico-Chemical Properties by Isosteric Replacement of 2-Aminothiazole with 2-Aminooxazole. Pharmaceuticals 2022, 15, 580

In the original publication [1], there was a mistake in assigning individual compounds to their structural subtype in Figure 2 and

Table 1. Structures, log k’_w, HepG2 cytotoxicity, and MIC against Mtb H37Ra of the title compounds.

Structure	Code	Ar	X	log k’w	HepG2 IC50 (µM)	Mtb H37Ra MIC (µg/mL)
	1a	pyridin-2-yl	S	1.857	>1000 *	31.25
	1b	pyridin-2-yl	O	0.854	>1000 *	62.5
	2a	pyridin-3-yl	S	1.251	>1000 *	250
	2b	pyridin-3-yl	O	0.436	>1000 *	31.25
	3a	pyridin-4-yl	S	1.306	>1000 *	250
	3b	pyridin-4-yl	O	0.396	>1000 *	15.625
	4b	5-Me-pyridin-3-yl	O	0.888	>1000 *	7.81
	5b	2-Me-pyridin-4-yl	O	0.714	>1000 *	3.91
	6a	2-Cl-pyridin-4-yl	S	2.013	>250 **	≥500
	6b	2-Cl-pyridin-4-yl	O	1.136	664.1	3.125
	7a	2-Cl-6-Me-pyridin-4-yl	S	2.319	>250 **	≥500
	7b	2-Cl-6-Me-pyridin-4-yl	O	1.430	959.4	<3.91
	8a	pyrazin-2-yl	S	1.222	n.d.	62.5
	8b	pyrazin-2-yl	O	0.154	n.d.	31.25
	9a	5-Cl-pyrazin-2-yl	S	1.941	n.d.	31.25
	9b	5-Cl-pyrazin-2-yl	O	0.958	n.d.	31.25
	10a	quinoxalin-2-yl	S	2.530	>50 **	≥250
	10b	quinoxalin-2-yl	O	1.493	>1000 *	15.625
	11a	pyridin-2-yl	S	3.102	>100 **	3.91
	11b	pyridin-2-yl	O	2.038	883.4	3.91
	12a	pyridin-3-yl	S	2.131	>25 **	≥500
	12b	pyridin-3-yl	O	1.118	610.3	125
	13a	pyridin-4-yl	S	2.190	>100 **	7.81
	13b	pyridin-4-yl	O	1.163	879.3	31.25
	14b	5-Me-pyridin-3-yl	O	1.478	>100 **	≥250
	15a	2-Cl-pyridin-4-yl	S	3.036	102.6	3.91
	15b	2-Cl-pyridin-4-yl	O	1.992	136.1	7.81
	16a	2-Cl-6-Me-pyridin-4-yl	S	3.314	n.d.	7.81
	16b	2-Cl-6-Me-pyridin-4-yl	O	2.251	n.d.	15.625
	17a	pyrazin-2-yl	S	2.365	n.d.	>50 [11]
	17b	pyrazin-2-yl	O	1.306	>1000 *	15.625
	18a	5-Cl-pyrazin-2-yl	S	3.173	n.d.	>100 [11]
	18b	5-Cl-pyrazin-2-yl	O	2.073	>100 **	15.625
	19a	quinoxalin-2-yl	S	3.583	n.d.	≥500
	19b	quinoxalin-2-yl	O	2.465	n.d.	≥500
	20b	phenyl	O	2.090	330.3	62.5
	CIP	-	-	-	-	0.25
	INH	-	-	-	-	0.25
	RIF	-	-	-	-	0.003–0.0015

* IC₅₀ above the highest tested concentration; ** exact IC₅₀ value could not be determined due to insolubility in the testing medium at higher concentrations; CIP—ciprofloxacin; INH—isoniazid; RIF—rifampicin; n.d.—not determined.

. In correction, subtype I comprises compounds 1–10, and subtype II comprises compounds 11–20. Also, for compounds 11–13 in Table 1, we unified the naming of the Ar substituent, using the pyridinyl convention instead of pyridyl (to achieve consistency with the rest of the paper). The corrected Figure 2 and Table 1 appear below. We made the same changes to Table S2 in the Supplementary Material. The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. This correction was approved by the academic editor. The original publication has also been updated.